Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform2
Hold1
Sell0
Strong Sell0

Share price forecast in JPY

The 4 analysts offering 12 month price targets for Takeda Pharmaceutical Co Ltd (ADR) have a median target of 16.39, with a high estimate of 18.10 and a low estimate of 14.89. The median estimate represents a 22.98% increase from the last price of 13.33.
High35.8%18.10
Med23.0%16.39
Low11.7%14.89

Dividends in JPY

Historical dividend information is not available for Takeda Pharmaceutical Co Ltd.
Div growth (TTM)--
More ▼

Earnings history & estimates in JPY

On Oct 31, 2024, Takeda Pharmaceutical Co Ltd (ADR) reported 2nd quarter 2025 earnings of 29.07 per share.
The next earnings announcement is expected on Jan 30, 2025.
Average growth rate-7.21%
Takeda Pharmaceutical Co Ltd (ADR) reported annual 2024 earnings of 46.04 per share on May 09, 2024.
Average growth rate+169.69%
More ▼

Revenue history & estimates in JPY

Takeda Pharmaceutical Co Ltd (ADR) had 2nd quarter 2025 revenues of 1.18bn. This bettered the 1.08bn consensus of the 2 analysts covering the company. This was 11.09% above the prior year's 2nd quarter results.
Average growth rate+3.35%
Takeda Pharmaceutical Co Ltd (ADR) had revenues for the full year 2024 of 4.26bn. This was 5.87% above the prior year's results.
Average growth rate+6.87%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.